Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
44.37
+0.60 (1.37%)
At close: May 15, 2025, 4:00 PM
44.41
+0.04 (0.09%)
After-hours: May 15, 2025, 4:43 PM EDT
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Protagonist Therapeutics stock ranges from a low of $51 to a high of $80. The average analyst price target of $66.5 forecasts a 49.88% increase in the stock price over the next year.
Price Target: $66.50 (+49.88%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 10, 2025.
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +80.30% | Apr 10, 2025 |
| Wedbush | Wedbush | Buy Reiterates $70 | Buy | Reiterates | $70 | +57.76% | Mar 28, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $60 → $76 | Strong Buy | Maintains | $60 → $76 | +71.29% | Mar 11, 2025 |
| BMO Capital | BMO Capital | Buy Reiterates $62 → $72 | Buy | Reiterates | $62 → $72 | +62.27% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $54 → $80 | Strong Buy | Maintains | $54 → $80 | +80.30% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
88.05M
from 434.43M
Decreased by -79.73%
Revenue Next Year
122.93M
from 88.05M
Increased by 39.61%
EPS This Year
-1.80
from 4.23
EPS Next Year
-1.49
from -1.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 236.3M | 302.4M | 711.9M | ||
| Avg | 88.1M | 122.9M | 207.0M | ||
| Low | 27.7M | 19.6M | 40.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -45.6% | 243.4% | 479.1% | ||
| Avg | -79.7% | 39.6% | 68.4% | ||
| Low | -93.6% | -77.7% | -67.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.97 | -0.56 | -0.37 | ||
| Avg | -1.80 | -1.49 | -1.40 | ||
| Low | -2.37 | -2.55 | -2.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.